Among various immunotherapeutic approaches, interleukin -12 ( IL -12 ) is particularly appealing because of its superior antitumor effects, which have been demonstrated in preclinical as well as clinical studies. However, IL -12 therapy was often accompanied by severe side effects due mainly to the supranormal induction of interferon -. To optimize the therapeutic efficacy and lower the side effects of IL -12, we have investigated the antitumor activity of combined IL -12 and granulocyte -macrophage colony -stimulating factor ( GM -CSF ) gene therapy in a highly malignant and poorly immunogenic murine hepatocellular carcinoma model. Using a versatile hydrodynamics -based DNA delivery method, we showed that the combined gene delivery of IL -12 and GM -CSF induced very strong antitumor cellular immunity and achieved significant therapeutic efficacy, whereas each cytokine gene alone yielded appreciable but less effects. We also observed that the combined therapy induced lower levels of interferon -than did IL -12 alone. These results suggest that combined IL -12 and GM -CSF therapy can render a stronger antitumor effect as well as lowering potential side effects. Cancer Gene Therapy ( 2001 ) 8, 751 -758 
O ne of the major causes of tumor progression is the weakening and loss of the host immune surveillance to tumor cells. Immunological approaches, including gene therapy, to induce and strengthen the host antitumor responses should repress tumor growth and even completely eradicate the tumors. Among various immunotherapeutic approaches, interleukin -12 ( IL -12 ) is particularly appealing because of its superior antitumor effects, which have been demonstrated in preclinical as well as clinical studies. 1 -5 IL -12 plays a critical role in cellular immune responses such as the induction of Th1 -mediated CD4 + T-cell differentiation, 6 stimulation of interferon -(IFN -) production, 7 and activation of natural killer cells. 8, 9 However, the antitumor activities of IL-12 were usually observed at high dosages 10 accompanied by severe side effects, 11 which were contributed mainly by the robust levels of IFN -production induced by IL -12. 12, 13 To optimize the therapeutic efficacy of IL -12, it is important to explore new strategies of combined immunotherapy, that employ lower doses of IL -12 in combination with other cytokines that cooperatively enhance the antitumor effects while mitigating the side effects. Granulocytemacrophage colony -stimulating factor (GM -CSF) , a hematopoietic growth factor, is a good candidate for the combined cytokine immunotherapy. Besides its function in regulating hematopoietic progenitor cell proliferation and differentiation, GM -CSF plays an important role in the activation and maturation of professional antigen-presenting cells ( APCs ) by up -regulating MHC molecules as well as co-stimulating pathways.
14 -16 GM -CSF also exhibits additional effects on the monocyte / macrophage system. 17 Preclinical and clinical studies have shown that GM -CSF is capable of producing antitumor cellular immunity through the above mechanisms. 18 -20 Because IL -12 and GM -CSF exert their functions through different mechanisms, one induces Th1 -mediated CD4 + cell differentiation while the other activates the APCs. We hypothesize that combination of these two cytokines should produce potent antitumor immunity.
To test the hypothesis of cooperative antitumor immunity enabled by IL -12 and GM -CSF, we chose to utilize a murine liver cancer model of hepatocellular carcinoma ( HCC ). 21 -23 This model has a high growth rate and very poor immunogenicity in the syngeneic BALB /c mice, proven to be difficult to treat with a number of conventional as well as gene therapy approaches. 21, 23 Likewise, clinical HCCs in human patients exhibit high malignancy, poor immunogenicity, and resistance to a variety of therapeutic modalities. More importantly, HCC is one of the most common cancers, afflicting millions of patients each year with rapid tumor progression and poor clinical prognosis. In the current study, we investigated the strategy of gene delivery to achieve combined antitumor effects by IL-12 and GM -CSF against the highly malignant and poorly immunogenic HCC model in mice. The in vivo gene delivery was accomplished by using a simple and versatile hydrodynamics -based method. 24, 25 Our results show that the combined gene therapy of IL -12 and GM -CSF induced very strong antitumor cellular immunity and achieved significant therapeutic efficacy, whereas each cytokine gene alone yielded appreciable but less effects. We also observed that GM -CSF modulated IL -12 expression and that the combined therapy induced lower levels of IFN -than IL -12 alone did. This decreased IFN -expression should lower the side effects associated with high levels of systemic IFN -.
MATERIALS AND METHODS

Animal and cell line
Eight -week -old male BALB/ c mice ( H -2 d ) were obtained from Jackson Laboratories ( Bar Harbor, ME ) and housed in pathogen -free conditions. The murine HCC cell line, BNL MEA.7R.1 ( BNL ), was purchased from American Type Culture Collection (Rockville, MD ). This cell line was derived from HCC in BALB /c mice after methylcholanthrene-induced carcinogenesis. 23 The cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat -inactivated fetal bovine serum, 2 mM Lglutamine, penicillin ( 100 U /mL ), and streptomycin ( 100 g/mL) at 378C in 5% CO 2 .
Plasmid construction
Mouse GM -CSF gene was cloned from murine spleen DNA by polymerase chain reaction (PCR ). The sequences of sense and antisense primers for PCR amplification were, respectively, 5 0 GCACTCAGAGAGAAAGGCTAAGG 3 0 and 5 0 GCTCTCGTTTGTCTTCCGCTGTCC 3 0 . The PCR product of GM -CSF gene was subcloned by blunt -end ligation into the NotI sites of a gene expression vector plasmid pXX -UF1, 26 which contains a cytomegalovirus immediate -early promoter, an SV-40 splicing site, and a polyA signal. The resulting plasmid is named pXX -GM -CSF. The mouse IL-12 cDNA was obtained from Invivogen ( San Diego, CA ). The two subunits ( p35 and p40 ) of the IL -12 were fused by a linker. The fusion IL -12 cDNA was subcloned by blunt -end ligation into the NotI sites of pXX -UF1 to obtain the expressing plasmid pXX -IL -12. The control plasmid is pXX -Neo containing a neomycinresistant gene without the therapeutic genes. The structures of pXX -GM -CSF, pXX -IL -12, and pXX -Neo are shown in Figure 1 .
Animal model and treatment protocol
To establish the murine HCC model with high reproducibility, we initially passaged the BNL cells in BALB /c mice subcutaneously by inoculating 2Â10 6 of the in vitrocultured cells ( resuspended in 100 L of PBS ) into the rear right flanks of the recipient animals. The established tumors were subsequently isolated and digested with collagenase. Such in vivo -passaged tumor cells (2Â10 6 cells resuspended in 100 L of PBS ) were once again inoculated subcutaneously in the right flank of new BALB /c recipients, which would later be treated with gene therapy methods as described below. The in vivo passage of BNL cells made the tumors grow rapidly and consistently. In vivo passage also excluded the influence of bovine serum and culture media.
For gene therapy treatment, the mice were randomly divided into four groups and each group consisted of six animals. On days 3 and 6 after tumor cell inoculation, each animal received a total of 50 g of plasmid (s ) injection via the tail vein with the hydrodynamics -based procedure. 24, 27 Tumor growth was monitored three times per week by measuring the two perpendicular tumor diameters with a caliper. Tumor sizes were presented as the product of two perpendicular tumor diameters. When the diameter of a tumor reached 20 mm or greater (around 22 days after tumor implantation) , the experiment was terminated and all the mice were sacrificed according to the rules of animal ethics, and tumor samples and spleen cells of all mice were collected for further analyses.
Histology and immunofluorescent staining
All the tumors were harvested at day 22 after inoculation, immediately frozen, and embedded in OCT compound. Serial 8-m cryosections were made for histological staining with H&E, or for immunofluorescent staining with anti -CD4 or anti -CD8 antibodies. For the examination of Tcell infiltration in the tumors, acetone-fixed cryosections were incubated for 1 hour at room temperature with anti -L3T4 (CD4 ) or anti -LY2 (CD8 ) polyclonal antibodies ( Pharmigen, San Diego, CA ). After three rinses, the sections were overlaid with Cy3 -Conjugated AffiniPure goat antirabbit IgG ( Jackson ImmunoResearch Laboratories ) . Cell nuclei were counterstained with 0.1% DAPI (Sigma, St. Louis, MO ) for 20 minutes. Photographs were taken with a Nikon TE -300 fluorescent microscopy equipped with a Spot I digital camera.
CTL assay
Spleen cells ( 2Â10 6 ) derived from BALB /c mice 22 days after tumor inoculation were co -cultured with -irradiated BNL cells ( 1Â10 5 ) for 5 days in vitro. Subsequently, the fresh target BNL cells labeled with 51 Cr were co -cultured in a total volume of 200 L with the spleen effector cells in round -bottomed 96 -well plates. A moloney leukemia virustransformed lymphoma cell line ( YAC -1) 28 was used as a target cell for negative control. After 4 hours of incubation, the supernatant was harvested and counted in a gamma counter, and specific lysis was calculated using the following formula: % specific lysis = [ (mean experimental cpm À mean spontaneous cpm ) / (mean maximum cpm À mean spontaneous cpm ) ].
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Enzyme -linked immunosorbent assay ( ELISA ) for cytokines
The serum concentrations of IL -12, GM -CSF, and IFNwere measured with ELISA kits ( Pharmigen ) according to the protocols provided by the manufacturer. The detection sensitivity limits for all three cytokines, IL -12, GM -CSF, and IFN -, were at 15.6 pg/ mL.
Statistics analysis
Data were presented as means ± SD. Comparisons of data from different groups were calculated by one -way ANOVA using SPSS program. The differences were considered significant when the P value was less than .05.
RESULTS
Combined gene therapy of IL-12 and GM -CSF produced potent antitumor effects against murine HCC
To examine whether IL -12 and GM -CSF could generate strong synergistic antitumor effects, a simple hydrodynamics -based procedure was used to deliver plasmid DNA in vivo, primarily in the liver, to achieve IL-12 and GM -CSF expression. In addition, we chose to use the murine HCC tumor model that was derived from the BNL cell line syngeneic to the BALB /c mice. This tumor model is one of the few HCC models available with poor immunogenicity and high malignancy. Flow cytometry showed undetectable MHC II and co -stimulatory molecules in BNL cells (data not shown ). Thus, this model represents a good candidate to test the combined cytokine gene therapy against a difficult target. To assure high reproducibility of the tumor model, we passaged the BNL cells in vivo for one generation before they were implanted in the recipient animals for cancer gene therapy studies. The freshly isolated BNL cells from the in vivopassaged tumors had a 100% tumor formation rate with consistent tumor sizes in the syngeneic recipient BALB /c mice.
To treat the tumors, the mice were injected twice with either the control plasmid or the therapeutic plasmids at 3 and 6 days after tumor cell inoculation. As shown in Figure 2 , treatment with IL -12 -expressing plasmid alone or GM -CSF -expressing plasmid alone reduced tumor growth when compared to the treatment with control plasmid pXX -Neo. However, the combined treatment with both IL -12 -expressing and GM -CSF -expressing plasmids demonstrated the strongest antitumor effects. The tumor sizes in the combined treatment group were about one third of the tumor sizes in the control plasmid -treated group. Complete tumor regression was observed in one animal in the combined treatment group. In addition, there were no overt adverse effects associated with the gene therapy protocol, consistent with previous reports. 10, 32 Due to the large tumor sizes in the control group, for humane reasons, all the experimental animals were sacrificed at 22 days after tumor inoculation. WANG, QIU, YE, ET AL: IL-12 AND GM-CSF GENE THERAPY Potent CTL reactions against HCC cells were induced by combined IL -12 and GM -CSF therapy Next, we evaluate the mechanism involving the antitumor activity. CTL assays were performed to examine whether the cell -mediated antitumor immunity was developed by the cytokine gene therapy. Spleen cells from the treated BALB /c mice were harvested and assayed for the CTL activities on day 22 after tumor implantation ( day 19 after the first plasmid injection ). As shown in Figure 3a , the tumorbearing mice treated by IL -12-expressing plasmid alone showed no appreciable specific CTL activity when compared to the control plasmid -treated mice, suggesting that IL-12 alone was not sufficient to launch a strong CTL reaction against the poorly immunogenic HCC tumor cells. Treatment with the GM -CSF -expressing plasmid showed elevated levels of specific CTL activity against the tumor cells. As expected, potent CTL activity was obtained in the mice treated with the combined cytokine plasmids pXX -IL-12 and pXX -GM -CSF. Moreover, the CTL activity is BNL cell -specific because there were no appreciable cell lysis activities against YAC -1 cells in all the experimental groups ( Fig 3b) . These results demonstrated that potent cellular antitumor immunity could indeed be induced by the combined treatment.
Both IL -12 and GM -CSF were required to induce intensive CD4 + and CD8
+ lymphocyte infiltrations in the tumor
To analyze the immunological effector cells involved in the specific antitumor immunity, we examined the T-lymphocyte populations that infiltrated into the tumors. The HCC tumor tissue samples were collected from the experimental animals. Immunostaining of CD4 or CD8 surface markers showed very few detectable CD4 + T-helper and CD8 + Tkiller lymphocytes that were infiltrated in tumors from mice treated by the control plasmid pXX -Neo (Fig 4) . As expected, high levels of both CD4 + and CD8 + T-cell infiltration were observed in the tumors treated with both plasmids expressing IL-12 and GM -CSF. Treatment with GM -CSF -expressing plasmid resulted in significant increases in both CD4 + and CD8 + T-cell infiltration, and treatment with IL -12 -expressing plasmid induced significant CD4 + T-cell infiltration, but with very little CD8 + Tcell infiltration (Fig 4) .
Co -delivery of IL -12 and GM -CSF genes generated prolonged IL -12 expression but lowered IFN -production
Next, we examined the gene expression levels of the cytokines after plasmid injections by measuring the serum concentrations of each individual cytokine. Based on the short -term nature of gene expression profiles rendered by the hydrodynamics-based plasmid DNA delivery method, serum samples were harvested at 8, 24, 48, 72 hours, and 1 week after plasmid injection. The concentrations of IL-12, GM -CSF, and IFN -were measured by ELISA. Previous experiments demonstrated that gene expression reached peak levels within 8 -24 hours after plasmid injection, followed by a rapid decline to basal levels. 27, 33 Such an expression pattern was also reflected in our experiments injected with IL -12 -expressing plasmid alone (Fig 5a ) or GM -CSFexpressing plasmid alone (Fig 5b) . However, we observed prolonged IL -12 production for up to 1 week by combined injection with both cytokine plasmids ( Fig 5a ) . However, such a prolonged effect was not observed in GM -CSF production. Thus, either the combined plasmids injection or GM -CSF single plasmid injection delivered the same levels and the same expression profiles of GM -CSF.
Because IFN -plays an important role not only in IL-12 -mediated antitumor activities but also in IL-12-induced toxic side effects, we therefore examined the IFNsecretion after plasmid injection. In the experimental animals treated with the control pXX -Neo plasmid or the GM -CSF -expressing plasmid, no IFN -could be detected in the serum above the background level ( 15.6 pg /mL detection limit of the ELISA kit ). As expected, IL -12 -expressing plasmid alone induced high levels of IFN -secretion in the serum. However, in animals treated with both IL -12-expressing and GM -CSF -expressing plasmids, lower serum concentrations of IFN -were detected, although high levels and prolonged IL -12 expression were detected in those mice (Fig 5c) .
DISCUSSION
Using a simple hydrodynamics-based in vivo DNA delivery method, we have investigated the antitumor effects of IL-12 and GM -CSF as well as their combination in treating a highly malignant and poorly immunogenic HCC model. Although IL -12 gene alone or GM -CSF gene alone rendered significant antitumor effects, a combination of both cytokine genes induced far more powerful antitumor activities. CTL assay suggested that potent tumor-specific CTL reactions against the HCC cells were induced only by two plasmids' co-injection. Despite a number of CD4 + T cells that were observed in tumors isolated from mice that have undergone IL -12 gene therapy, intensive CD4 + and CD8 + T-cell infiltrations were observed only in the tumors isolated from mice treated with the combined IL -12 and GM -CSF gene therapy. Together, these results suggest that the combined treatment of IL -12 and GM -CSF can induce stronger tumor-specific cellular immunity.
Liver cancers, particularly the HCC, afflict millions of patients each year worldwide. Yet currently treatment is unsatisfactory and the prognosis is often poor. Previously, viral vector -mediated gene therapy with suicidal TK gene and the prodrug gancyclovir has been investigated in treating the HCC liver cancer model based on the BNL cell in syngeneic BALB /c mice. However, because BNL cells are refractory to infection by both adenovirus and adeno-associated virus, only very limited gene transfer efficiency has been achieved intratumorally, which limited the efficacy. A combined gene therapy with IL -12 gene and the suicide TK gene delivered by adenovirus vectors slightly improved the outcomes in treating the same HCC model. 22 However, even if intratumoral gene therapy could repress the tumor locally, this strategy has its limitation in treating cancers after their metastasis. Recently, the same HCC cancer model was used in another study where a novel combined immune gene therapy strategy was devised. 21 In that study, a BNL cell line was isolated, which uniformly expressed the B7 co -stimulatory molecule for antigen presentation. The B7 molecule was absent in the parental cells, but was re -introduced via stable transfection and selection for the B7 gene expression. The HCC tumor derived from the B7 -expressing cell line had enhanced antigen presentation capability, hence more immunogenicity. Such a tumor was more sensitive to the IL -12 gene therapy. 21 Nonetheless, a stably transfected cell line with B7 gene would not mirror the real situation in cancer patients, whose tumor could not be conveniently transfected and selected for B7 gene expression. In our study, we explored the combined gene therapy strategy to induce systemic immune response against the HCC cells by using two different cytokines that act on distinct mechanisms for systemic immune stimulation. Given the fact that the HCC model employed here had a very rapid growth rate, reaching terminal stages in merely 3 weeks if left untreated, the therapeutic effects rendered by the combined cytokine gene therapy are considered rather efficacious. In fact, no clinical HCC can proceed in such a rapid fashion. Therefore, the combined cytokine gene therapy investigated in this study may have a wider window of opportunity to launch a stronger immune response and to achieve even better antitumor effects in clinical settings.
Upon examination of serum cytokine concentrations, two interesting phenomena were observed in our study. First, co -delivery of IL -12 and GM -CSF genes resulted in prolonged high -level IL -12 production for over a week. This is exceptional because previous studies demonstrated that the hydrodynamics -based method only generated transient high -level transgene expression. 24, 25 This transient expression profile held true not only for IL -12 gene delivery alone, but also for GM -CSF gene delivery, irrespective of whether the gene was delivery alone or co-delivered with IL -12. This result suggests that IL-12 and GM -CSF together could positively regulate prolonged IL -12 gene expression, even if the GM -CSF gene expression was in a transient manner. The second interesting phenomenon from our study is the dampened IFN -production induced by IL -12 and GM -CSF gene co -delivery. The serum IFNlevels were much higher after induction by IL -12 gene delivery alone than those after induction by both the IL -12 and GM -CSF genes. The lower levels of IFN -production in the case of IL -12 and GM -CSF gene co-delivery were not due to lowered levels of IL -12 production because the serum IL -12 levels were essentially the same regardless of whether the gene was delivered alone or together with GM -CSF. In fact, the IL-12 levels were even higher and prolonged in the case of gene co -delivery. Therefore, the lowered IFN -production by IL -12 and GM -CSF plasmid co -delivery may potentially be contributed by some unknown antagonist effects. Although the exact mechanisms remain elusive and require further studies, the outcome of such a combined gene therapy regimen, thus the prolonged IL -12 production accompanied by the lowered IFNinduction, should have significant clinical relevance in enhancing the antitumor immune response while lowering the systemic side effects. This is because IFN -induction is a major factor responsible for the IL -12 -induced antitumor effects, and it is also a major cause for the IL -12-induced toxicity. The latter is particularly problematic in clinical settings when IFN -reaches very high levels. Based on our results, the combined delivery of both genes indeed elicited higher and long -lasting expression of IL -12 accompanied by better therapeutic efficacy. In addition, in our study the peak serum concentration of IL -12 was about 0.2 g/mL serum, which was lower than the maximum tolerated dosage in mice. 3 No apparent side effects were observed in the experimental animals. Moreover, one of the side effects of IL -12 is the hematological toxicity, whereas GM -CSF is a hematopoietic growth factor. Thus, there exist additional advantages for the combined IL -12 and GM -CSF gene therapy.
In summary, using the hydrodynamics-based DNA delivery method, we have shown that combined IL -12 and GM -CSF gene therapy could launch strong CTL reactions against the highly malignant and poorly immunogenic HCC cancer model. Such immune responses rendered a strong antitumor effect and profound therapeutic efficacy. Even though the hydrodynamics -based DNA delivery method in its current stage cannot be used in clinical applications due to the fluid volume and high pressure involved, this method indeed provides a rapid and versatile tool for the proof -ofconcept gene therapy investigations. The therapeutic results obtained in this study, however, support further exploration of the combined cytokine gene therapy with viral vectors such as the adenoviral vector and the adeno -associated viral vector. The latter offers highly efficient gene transfer in vivo in tissues such as liver and muscle, while lacking both cytotoxicity and systemic toxicity. Equipped with an inducible promoter, such as the Tet -on or Tet -off system for regulated transgene expression, the adeno-associated viral vector remains a viable alternative vehicle for cancer gene therapy using cytokines and other secretable therapeutic proteins including antiangiogenesis factors such as endostatin and angiostatin. 34, 35 
